Oncotelic Therapeutics, Inc. (OTLC)
2025-06-30 | 2024-09-30 | |||
|---|---|---|---|---|
| Less goodwill impairment due to market capitalization | - | 3,200 | ||
| Research and development | 0.297 | 0.48 | ||
| General and administrative | 65.672 | 80.277 | ||
| Total operating expenses | 65.969 | 3,280.757 | ||
| Loss from operations | -65.969 | -3,280.757 | ||
| Interest expense, net | 207.78 | 205.616 | ||
| Loss on extinguishment / conversion of debt | - | - | ||
| Change in fair value of derivative on debt | 484.198 | 114.722 | ||
| Reimbursement for expenses - related party | - | - | ||
| Total other income (expense) | 276.418 | -90.894 | ||
| Net income (loss) before non-controlling interests | 210.449 | -3,371.651 | ||
| Net income (loss) attributable to non-controlling interests | -67.407 | -67.165 | ||
| Net income (loss) attributable to oncotelic therapeutics, inc | 277.856 | -3,304.486 | ||
| Basic net income (loss) per share attributable to common stock | - | -0.01 | ||
| Basic weighted average common stock outstanding | 408,292,720 | 407,289,888 | ||
| Diluted net income per share attributable to common stock | - | -0.01 | ||
| Diluted weighted average common stock outstanding | 452,809,058 | 407,289,888 | ||